Enanta Pharmaceuticals (ENTA) EBIAT (2016 - 2025)
Enanta Pharmaceuticals' EBIAT history spans 14 years, with the latest figure at -$11.9 million for Q4 2025.
- For Q4 2025, EBIAT rose 46.44% year-over-year to -$11.9 million; the TTM value through Dec 2025 reached -$71.5 million, up 31.82%, while the annual FY2025 figure was -$81.9 million, 29.43% up from the prior year.
- EBIAT reached -$11.9 million in Q4 2025 per ENTA's latest filing, up from -$18.7 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$11.9 million in Q4 2025 to a low of -$39.1 million in Q2 2023.
- Average EBIAT over 5 years is -$26.8 million, with a median of -$27.2 million recorded in 2022.
- Peak YoY movement for EBIAT: plummeted 267.11% in 2021, then skyrocketed 46.44% in 2025.
- A 5-year view of EBIAT shows it stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then dropped by 15.25% to -$33.4 million in 2023, then skyrocketed by 33.28% to -$22.3 million in 2024, then skyrocketed by 46.44% to -$11.9 million in 2025.
- Per Business Quant, the three most recent readings for ENTA's EBIAT are -$11.9 million (Q4 2025), -$18.7 million (Q3 2025), and -$18.3 million (Q2 2025).